{"id":5538,"date":"2022-02-17T07:00:00","date_gmt":"2022-02-17T07:00:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/"},"modified":"2022-02-17T07:00:00","modified_gmt":"2022-02-17T07:00:00","slug":"nanexa-publicerar-bokslutskommunike-for-2021","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/","title":{"rendered":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2021"},"content":{"rendered":"<div class=\"mfn-preamble\">\n<p><strong>Ytterligare utv\u00e4rderingsavtal och positiva resultat i preklinisk utredning av NEX-18<\/strong><\/p>\n<\/div>\n<div class=\"mfn-body\">\n<p><strong>V\u00e4sentliga h\u00e4ndelser under fj\u00e4rde kvartalet 2021<\/strong><\/p>\n<ul>\n<li>Nanexa mottog beslut fr\u00e5n Finansinspektionen att betala sanktionsavgift om 1 000 000 kronor avseende en h\u00e4ndelse som intr\u00e4ffade 2017.<\/li>\n<li>Nanexa tecknade ytterligare ett s\u00e5 kallat Material Transfer and Feasibility Study Agreement med en av bolagets befintliga kunder, f\u00f6r utv\u00e4rdering av PharmaShell\u00ae-teknologin med en specifik biologisk l\u00e4kemedelssubstans.<\/li>\n<li>Kompletterande prekliniska studier inleddes i oktober f\u00f6r att utreda vad som har orsakat de m\u00e5ttliga hudreaktioner som uppkom i bolagets fas I-studie med NEX-18, en dep\u00e5beredning av azacitidin baserad p\u00e5 PharmaShell.<\/li>\n<\/ul>\n<p><strong>V\u00e4sentliga h\u00e4ndelser efter periodens utg\u00e5ng<\/strong><\/p>\n<ul>\n<li>Nanexa beviljades ett patent i USA (US 11,214,865 B2) avseende en ALD-reaktor anpassad f\u00f6r storskalig produktion av PharmaShell-belagda l\u00e4kemedel.<\/li>\n<li>Nanexa meddelade att bolagets prekliniska utredning indikerar orsaken till och en potentiell l\u00f6sning p\u00e5 de m\u00e5ttliga hudreaktioner som uppkom i den kliniska studien med NEX-18. Med dessa resultat expanderar Nanexa det prekliniska programmet f\u00f6r att optimera formuleringen av NEX-18 och projektet v\u00e4ntas g\u00e5 in i klinik igen under n\u00e4sta \u00e5r.<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 oktober \u2013 31 december 2021<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 670 (549) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -13 045 (-7 768) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -13 087 (-7 814) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -0,26 (-0,37) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: -14 139 (-13 300) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 105 660 (12 691) kSEK<\/li>\n<\/ul>\n<p><strong>Sammanfattning av rapportperioden 1 januari \u2013 31 december 2021<\/strong><\/p>\n<ul>\n<li>Oms\u00e4ttningen uppgick till: 2 374 (2 367) kSEK<\/li>\n<li>R\u00f6relseresultatet (EBIT) uppgick till: -35 821 (-21 489) kSEK<\/li>\n<li>Resultatet efter skatt uppgick till: -35 999 (-21 736) kSEK<\/li>\n<li>Resultat per aktie uppgick till: -1,01 (-1,09) SEK<\/li>\n<li>Periodens kassafl\u00f6de uppgick till: 92 969 (1 313) kSEK<\/li>\n<li>Likvida medel vid periodens utg\u00e5ng: 105 660 (12 691) kSEK<\/li>\n<li>Styrelsen f\u00f6resl\u00e5r att ingen utdelning l\u00e4mnas<\/li>\n<\/ul>\n<p><em>Siffror inom parentes avser motsvarande period f\u00f6reg\u00e5ende \u00e5r.<\/em><\/p>\n<p>Rapporten i sin helhet finns tillg\u00e4nglig p\u00e5 v\u00e5r hemsida via f\u00f6ljande l\u00e4nk, <a href=\"https:\/\/nanexa.com\/finansiella-rapporter\/\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/nanexa.com\/finansiella-rapporter\/<\/a>.<\/p>\n<p><strong>Investerarpresentation 17 februari kl 14:30<\/strong><\/p>\n<p>Webcast och telekonferens med fr\u00e5gestund h\u00e5lls den 17 februari 2022, kl 14:30 (CET) med styrelseordf\u00f6rande G\u00f6ran Ando, vd David Westberg och styrelseledamot Bengt Gustavsson.<\/p>\n<p>Webcast: https:\/\/tv.streamfabriken.com\/nanexa-q4-2021<br \/>Telekonferens: SE: +46856642706 | UK: +443333009260 | US: +16467224902 <\/p>\n<\/div>\n<div class=\"mfn-footer mfn-contacts\">\n<p><strong class=\"mfn-heading-1\">F\u00f6r mer information kontakta:<\/strong><\/p>\n<hr\/>\n<p>David Westberg \u2013 VD, Nanexa AB (publ)\u00a0<br \/>Telefon: 0709-42 83 03<br \/>E-post:\u00a0<a href=\"mailto:david.westberg@nanexa.se\" target=\"_blank\" rel=\"nofollow noopener\">david.westberg@nanexa.se<\/a><br \/><a target=\"_blank\" href=\"http:\/\/www.nanexa.com\" rel=\"nofollow noopener\">www.nanexa.com<\/a><\/p>\n<p>Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-about\">\n<p><strong class=\"mfn-heading-1\">Om Nanexa AB (publ)<\/strong><\/p>\n<hr\/>\n<p>Nanexa AB \u00e4r ett nanoteknologiskt drug delivery-f\u00f6retag fokuserat p\u00e5 utvecklingen av PharmaShell\u00ae, ett nytt och banbrytande drug delivery-system med stor\u00a0potential inom ett flertal substanstyper och indikationsomr\u00e5den. Inom ramen f\u00f6r PharmaShell\u00ae utvecklar Nanexa egna produkter och har samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland\u00a0AstraZeneca.<\/p>\n<p>Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n<div class=\"mfn-footer mfn-regulatory mfn-regulatory-mar\">\n<p><em>Denna information \u00e4r s\u00e5dan information som Nanexa \u00e4r skyldigt att offentligg\u00f6ra enligt EU:s marknadsmissbruksf\u00f6rordning. Informationen l\u00e4mnades, genom ovanst\u00e5ende kontaktpersons f\u00f6rsorg, f\u00f6r offentligg\u00f6rande den 2022-02-17 08:00 CET.<\/em><\/p>\n<\/div>\n<div class=\"mfn-footer mfn-attachment mfn-attachment-general\">\n<p><strong class=\"mfn-heading-1\">Bifogade filer<\/strong><\/p>\n<hr\/>\n<p><a class=\"mfn-primary\" href=\"https:\/\/storage.mfn.se\/0a658951-bbb0-42cb-a5ed-e63133931dea\/nanexa-bokslutskommunike-2021.pdf\" target=\"_blank\" rel=\"nofollow noopener\">Nanexa Bokslutskommunik\u00e9 2021<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Ytterligare utv\u00e4rderingsavtal och positiva resultat i preklinisk utredning av NEX-18<\/p>\n","protected":false},"template":"","class_list":["post-5538","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-report-interim-q4_sv","mfn-news-tag-mfn-report-interim_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn-regulatory-mar_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-report_sv","mfn-news-tag-mfn-regulatory_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2021 - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2021 - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Ytterligare utv\u00e4rderingsavtal och positiva resultat i preklinisk utredning av NEX-18\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2021\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2021\\\/\",\"name\":\"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2021 - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-02-17T07:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2021\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2021\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-publicerar-bokslutskommunike-for-2021\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2021\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2021 - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2021 - Nanexa AB","og_description":"Ytterligare utv\u00e4rderingsavtal och positiva resultat i preklinisk utredning av NEX-18","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/","name":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2021 - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-02-17T07:00:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-publicerar-bokslutskommunike-for-2021\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa publicerar bokslutskommunik\u00e9 f\u00f6r 2021"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/5538","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=5538"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}